HTB

CROI 27 (virtual) 2020

Conference on Retroviruses and Opportunistic Infections (CROI 2020)

Predicted diabetes risk with first-line ART regimens: results from the ADVANCE trial

Dolutegravir-based ART is safe and effective for pregnant women: first results from the VESTED trial

A step forward for AAV-mediated delivery of bNAbs

Conference on Retroviruses and Opportunistic Infections (CROI 2020)

CROI 2020: Special session on COVID-19

Long-acting cabotegravir and rilpivirine injections support two-monthly dosing

Safety and PK of bNAb elipovimab (GS-9722) support two-weekly dosing

First results with long-acting capsid inhibitor GS-6207: oral and subcutaneous formulations for use in naïve and multidrug resistance

Predicted diabetes risk with first-line ART regimens: results from the ADVANCE trial

London patient is second person to be cured of HIV from allogeneic stem-cell transplant

The London Patient tells his story as second person cured of HIV